Adaptive Biotechnologies Corp
(NAS:ADPT)
$
6.29
-0.15 (-2.33%)
Market Cap: 950.41 Mil
Enterprise Value: 791.33 Mil
PE Ratio: 0
PB Ratio: 4.25
GF Score: 78/100 Adaptive Biotechnologies Corp at Cowen HealthCare Conference Transcript
Mar 03, 2020 / 01:40PM GMT
Release Date Price:
$25.72
(-4.03%)
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
All right. Good morning, everybody. It's our pleasure to welcome Chad Robins from Adaptive Biotechnologies to the Cowen Conference. Thanks for being here, Chad. Adaptive's immune profiling platform is well-validated and its product pipeline continues to advance. Chad and his team have successfully demonstrated their regulatory and reimbursement prowess via clonoSEQ and also via many clonoSEQ and immunoSEQ-related partnerships. Over the next 30 minutes or so, we're going to focus on the outlook for 2020, progress across the base business as well as pipeline developments and the associated time lines. So again, thanks, Chad, for joining us.
Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman
Thanks for having me here, Doug.
Questions & Answers
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
I wanted to spend a few minutes just going back to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot